Drug Approved to Help Young Patients Battle a Rare Cancer
MONDAY, Jan. 2, 2023 (HealthDay News) -- Children and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big
Stay updated with breaking news from John Glod. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MONDAY, Jan. 2, 2023 (HealthDay News) -- Children and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big
New research from VCU Massey Cancer Center published last month in Cell Reports demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known as neuroblastoma.
RICHMOND, Va. — New research from VCU Massey Cancer Center — published this week in Cell Reports — demonstrated that a novel targeted therapy could be an effective treatment option
New research from VCU Massey Cancer Center -; published Thursday in Cell Reports -; demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known as neuroblastoma.
E-Mail IMAGE: This image shows expression of a specific ferroptosis marker called TfR1 in MYCN-amplified neuroblastoma tissues before and after treatment with auranofin, an FDA-approved drug for rheumatoid arthritis. view more Credit: VCU Massey Cancer Center Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths. Anthony Faber, Ph.D., and a team of researchers at VC...